Retapamulin is an antibiotic in the new class of pleuromutilins. Pleuromutilin is a natural antibacterial product derived from the fungus Clitopilus passeckerianus. Similar as macrolides, tetracyclines and aminoglycosides, retapamulin inhibits the bacterial protein synthesis, although is uses a different binding place on ribosomal subunit 50S.

Retapamulin specifically binds in the region of the P-site and peptidyl transferase centre (PTC). By virtue of binding to the PTC, retapamulin inhibits the transfer of the developing amino acid chain onto the following tRNA. Other mechanisms used by retapamulin are partially blocking P-site interactions and preventing normal formation of active 50S ribosomal subunit.



Because of its specific mechanism of action, retapamulin does not display target specific cross-resistance with other antibiotics.

Bacterial skin infections caused by S. aureus and S. pyogenes strains are sensitive to the bacteriostatic effects of retapamulin.

Irritation at the application site is the most common adverse effect.

EPAR of retapamulin.